SGLT2 Inhibitors in Type 2 Diabetes Linked to Lower Risk of Developing GI Cancers
Damian McNamara, MAVANCOUVER, Canada — Use of sodium glucose cotransporter-2 (SGLT2) inhibitors is associated with a reduced risk of gastrointestinal (GI) cancers among patients withtype 2 diabe
SGLT2 Inhibitors in Type 2 Diabetes Linked to Lower Risk of Developing GI Cancers
Damian McNamara, MAVANCOUVER, Canada — Use of sodium glucose cotransporter-2 (SGLT2) inhibitors is associated with a reduced risk of gastrointestinal (GI) cancers among patients withtype 2 diabe